|
⚲
|
| Keyboard |
| Deep Track Capital LP
✚
|
|
|---|---|
| CRD # | 312459 |
| SEC # | 801-120500 |
| CIK # | 0001856083 |
| AUM | 8,373.4 M (2026-03-31) |
| Employees | 19 (63% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-409-0810 |
| Address | 200 Greenwich Avenue Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Wed, 15 Jul 2026 | Draig Therapeutics Closes $65M Series B Led by Deep Track Capital — citybiz |
| Tue, 14 Jul 2026 | Attovia Therapeutics Investors Include Deep Track Capital, Frazier Life Sciences, Alamar Biosciences and Goldman Sachs — Moomoo |
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5. Fees and Compensation Deep Track will be entitled to the fees, including Management Fees, Incentive Allocation and Carried Interest, and the reimbursement of expenses as provided in the governing documents of the Funds. Management Fee Deep Track will receive a quarterly management fee (the “Management Fee”) from the Flagship Fund paid in advance of each fiscal quarter, generally 200 basis points annually of assets under management, with founding investors in the Feeder Funds being charged a reduced rate, which may vary depending on the size of their investment maintained in the Flagship Funds. Deep Track will receive a Management Fee from the Special Opportunities Fund of 200 basis points annually based on “invested cost”, paid at the beginning of each fiscal quarter. In the sole discretion of Deep Track, the Management Fee may be waived, reduced or calculated differently with respect to any underlying investor of the Funds, including, without limitation, any employee or personnel of Deep Track and their family members and estate planning vehicles. The Flagship Fund Management Fee will be prorated and payable as of a subscription date for any capital contribution by an underlying Feeder Fund investor that is effective as of a date other than as of the first day of a fiscal quarter. In the event of a withdrawal by an underlying Feeder Fund investor other than as of the last day of a fiscal quarter, Deep Track will refund an amount equal to the pro rata portion of the Management Fee, based on the actual number of days remaining in such fiscal quarter. Incentive Allocation As set forth in Item 6 below, the Flagship Fund General Partner and the Special Opportunities Fund General Partner are eligible to receive performance-based allocations from the Funds. The Flagship Fund General Partner is eligible to receive up to 20% of profits from the Master Fund, generally subject to a “loss carry forward”. The Special Opportunities Fund General Partner is eligible to receive a carried interest of 20% from the Onshore Special Opportunities Fund, subject to a waterfall calculation. The Confidential Private Placement Memorandum (as supplemented from time to time) (collectively, the “Offering Documents”) of each Fund include further details on fees and compensation and related matters. Other Fees and Expenses Deep Track and its affiliates may be entitled to receive (i) cash and non-cash transaction, consulting, management, investment banking, monitoring, closing and other similar fees in connection with the purchase, monitoring or disposition of investments in the Funds’ portfolio companies, including warrants, options, derivatives and other rights in respect of securities owned by the Funds, (ii) topping, break-up and other similar fees payable in connection with unconsummated transactions by the Funds and (iii) cash and non-cash directors’ fees, including warrants, options, derivatives and other rights in respect of securities owned by the Funds, in each case, paid by a portfolio company of the Funds. A percentage of these fees (net of out-of-pocket expenses incurred by Deep Track or its affiliates), but excluding amounts received from co-investors and amounts received by Consultants, will be applied to reduce the Management Fee pursuant to the relevant investment management agreements between the Funds and Deep Track. As set forth in such agreements, such fees, to the extent such fees are attributable to investors in the Funds that are subject to Management Fees, are typically subject to a 100% offset against the Management Fee. Moreover, Deep Track and its personnel can be expected to receive certain intangible or other benefits or perquisites arising or resulting from their activities on behalf of the Funds that will not reduce any compensation received by Deep Track from the Funds or otherwise be shared with the Funds, their investors or the Funds’ portfolio companies. For example, airline travel or hotel stays incurred as expenses of the Funds typically result in “miles” or “points” or credit in loyalty/status programs, and such benefits or amounts will, whether or not de minimis or difficult to value, inure exclusively to Deep Track or such personnel (and not the Funds, their investors or the portfolio companies) even though the cost of the underlying service is borne by the Funds or the portfolio companies. Deep Track may engage and retain, from time to time, operating executives, operating partners, executive advisors, senior advisors, special advisors, consultants and other similar professionals who may or may not be affiliates or former employees of Deep Track (collectively, the “Consultants”) and who are expected, from time to time, to receive payments from, or performance- based compensation with respect to, portfolio companies (as well as from Deep Track or the Funds). Such amounts will not reduce the Management Fee or the Incentive Allocation or Carried Interest. Any costs or expenses of or otherwise relating to Consultants that are not otherwise paid by the portfolio companies will generally be treated as expenses of the Funds and therefore borne by the Funds. Expenses Each Fund will bear its own costs and expenses, including, without limitation, the Management Fee (as described above) and all cost and expenses related to its operation, including, but not limited to, all (i) expenses related to the research, due diligence, structuring, financing, refinancing, consummation, holding, monitoring, operation or disposition of actual and prospective investments (whether or not consummated), including, but not limited to, brokerage and prime brokerage fees, commissions and expenses, due diligence costs, fees and expenses related to obtaining research and market data (including, without limitation, any information technology hardware, software or other technology incorporated into the cost of obtaining such research and market data), investment ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7. Types of Clients Deep Track provides advisory services to private investment funds. The private investment funds operate as pooled investment vehicles in a “master-feeder” fund structure for the Flagship Fund, where all investable assets are invested through the Master Fund, an exempted company incorporated under the laws of the Cayman Islands. In the Special Opportunities Fund investible assets are invested through the Onshore Special Opportunities Fund. Investment advice is provided directly to the Funds and not individually to investors in the Funds. Generally, the Funds require a minimum initial subscription from investors (although Deep Track or the applicable Fund’s directors have discretion to reduce such minimums in certain circumstances) and investors must meet certain suitability requirements. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Guardant Health Inc | 0.3 | ||
| Health Sciences Acquisitions Corp | 0.3 | ||
| Tarsus Pharmaceuticals Inc | 0.3 | ||
| Vaxcyte Inc | 0.2 | ||
| Structure Therapeutics Inc | 0.2 | ||
| Axsome Therapeutics Inc | 0.2 | ||
| Ocular Therapeutix Inc | 0.2 | ||
| Vera Therapeutics Inc | 0.2 | ||
| Alumis Inc | 0.1 | ||
| ISIS Pharmaceuticals Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Deep Track Special Opportunities Fund LP | 2025-11-19 | 284.6 M | |
| HF | Deep Track Biotechnology Master Fund Ltd | 2021-07-08 | 8,088.7 M |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 8.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 8.4 |
| By Discretionary | ||
| Discretionary | 5 | 8.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 8.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.6 | |
| United States Persons | 2.8 | |
| Total | 5 | 8.4 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001856083] | |
| 3 | [0001856083] | |
| 4 | [0001856083] | |
| SC 13D | [0001856083] | |
| SC 13G | [0001856083] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 5493005XI3U41MXN3456 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Dynavax Technologies Corp DVAX
Common Stock, par value $0.001 per share
|
2026-02-10 | Tender | 15,726,349 | ||
|
LB Pharmaceuticals Inc LBRX
Pre-Funded Warrants (Right to Buy) · derivative
|
2026-02-06 | Buy | 93,925 | $21.17 | 1,988,392 |
|
LB Pharmaceuticals Inc LBRX
Pre-Funded Warrants (Right to Buy) · derivative
|
2026-02-06 | Buy | 378,444 | $21.17 | 8,011,659 |
|
Nektar Therapeutics NKTR
Common Stock
|
2024-05-10 | Sell | 56,000 | $1.78 | 99,680 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Eldridge Credit Advisers LLC
✚
|
NY | 8,459.5 M |
|
Vista Credit Partners LP
✚
|
NY | 8,422.8 M |
|
Chatham Asset Management LLC
✚
|
NJ | 8,271.7 M |
|
Aequim Alternative Investments LP
✚
|
CA | 8,248.0 M |
|
Ironwood Capital Management Corp
✚
|
CA | 8,225.8 M |
|
Wincoram Asset Management LLC
✚
|
TX | 8,186.1 M |
|
Starboard Value LP
✚
|
NY | 8,151.9 M |
|
Overlook Investments Limited
✚
|
8,092.8 M | |
|
Overlook Investments LP
✚
|
8,092.8 M | |
|
Context Capital Management LLC
✚
|
CA | 8,008.2 M |